---
title: "Mortality and Predictors of Death in US Adults with Down Syndrome: Medicaid/Medicare Analysis"
id: "medrxiv-6-death-in-people-with-down-syndrome-mortality-statistics-and-novel-predictors-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-death-in-people-with-down-syndrome-mortality-statistics-and-novel-predictors-in"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.17.26358090v1?rss=1"
published_at: "2026-07-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Mortality and Predictors of Death in US Adults with Down Syndrome: Medicaid/Medicare Analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-death-in-people-with-down-syndrome-mortality-statistics-and-novel-predictors-in
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.17.26358090v1?rss=1)
- **Published At:** 2026-07-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preprint analyzed 11 years of US **Medicaid and Medicare** claims to describe mortality and predictors of death in adults with **Down syndrome**. - Cohort included 137,293 adults with Down syndrome; 30,894 (22.5%) died during the study period. Mean age at death was 55 years (SD 10). - Mean age at death among those with a claim for **Alzheimer’s disease** was 59 years (SD 7); for those without it was 52 years (SD 12). - Deaths were identified using the Centers for Medicare and Medicaid Services reported date of death; health conditions were ascertained from ICD-9 and ICD-10 claims codes. - The study used a case-control design with risk-set sampling to match the time distribution of incident Alzheimer’s disease in the sample. - A gradient-boosted tree (machine-learning) approach was trained to rank the strongest predictors of death in the full cohort and within age strata. - The most influential predictors of mortality were any claim for **dementia**, any claim for **pneumonia**, recurring claims for **cardiovascular disease** three years before index death, and any claim for **heart failure** and **epilepsy**. - Authors conclude findings align with prior clinical work and point to potentially intervenable areas to reduce mortality in people with Down syndrome. - The report is a preprint, not peer-reviewed. Funding reported from the National Institute on Aging (R01AG073179). Competing interests and IRB exemption are disclosed.
## Clinical Analysis & Structured Key Points
Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint Death in People with Down syndrome: Mortality statistics and novel predictors in US Medicaid and Medicare enrolled adults. View ORCID Profile Salina Tewolde, View ORCID Profile Anthony J Rosellini, View ORCID Profile Amy Michals, View ORCID Profile Brian G Skotko, View ORCID Profile Juan Fortea, View ORCID Profile Bernard Khor, View ORCID Profile Samuel Handelman, View ORCID Profile Eric Rubenstein doi: https://doi.org/10.64898/2026.07.17.26358090 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract People with Down syndrome have higher age-specific mortality rates compared to the general population as well as peers with other intellectual and developmental disabilities. While a large proportion of mortality is attributable to Alzheimers disease, many die prior to Alzheimers diagnosis and some live to old ages, dying without Alzheimers. Our objectives were to use 11 years of Medicaid and Medicare data to describe characteristics and factors related to death in adults with Down syndrome and use machine learning to identify which conditions most strongly predict death in the full population and stratified by age. We identified death using Center for Medicare and Medicaid Systems reported date of death health conditions using ICD 9 and 10 codes. We used a case-control design with risk set sampling to have that controls to mimic the distribution of times of incident Alzheimers disease. We trained gradient boosted trees to identify strongest predictors. Our cohort included 137,293 adults with Down syndrome. Among those, 30,894 (22.5%) died during the study period. Mean age at death among those who died was 55 years (SD=10). Mean age of death in those with Alzheimers disease was 59 (SD=7) and those without was 52 (SD=12). The most influential predictors of mortality were any claim for dementia, any claim for pneumonia, re-occurring claim for cardiovascular disease three years before index death, and any claim for heart failure and epilepsy. Our results align with previous clinical work and highlight intervenable areas to reduce mortality in the Down syndrome population. Competing Interest Statement Dr. Skotko occasionally consults on the topic of Down syndrome through Gerson Lehrman Group. He receives remuneration from Down syndrome non-profit organizations for speaking engagements and associated travel expenses. Within the past two years, he has received research funding from AC Immune, and LuMind IDSC Down Syndrome Foundation to conduct clinical trials for people with Down syndrome. Dr. Skotko is occasionally asked to serve as an expert witness for legal cases where Down syndrome is discussed. Dr. Skotko serves in a non-paid capacity on the Honorary Board of Directors for the Massachusetts Down Syndrome Congress and the Professional Advisory Committee for the National Center for Prenatal and Postnatal Down Syndrome Resources. Dr. Skotko has a sister with Down syndrome. Dr. Fortea has served on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Novo Nordisk, Perha, Roche, Zambn, Spanish Neurological Society, T21 Research Society, Lumind foundation, Jrme-Lejeune Foundation, Alzheimers Association, National Institutes of Health USA, and Instituto de Salud Carlos III. JF reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). Funding disclosure This work was funded by the National Institute of Aging R01AG073179 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This project was considered exempted research by the Boston University Medical Campus Institutional Review Board. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes FUNDER INFORMATION DECLARED National Institute on Aging, https://ror.org/049v75w11, R01AG073179 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Next Posted July 20, 2026. Download PDF Print/Save Options Author Declarations Supplementary Material Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more
## Related Clinical Research

- [Sanofi Pompe drug shortages, Jazz Pharma buys Actio, and Lilly’s Foundayo OKed in U.K.](https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-sanofi-drug-shortage-a-jazz-pharma-deal.md)
- [Pre-diagnostic 1-year prevalence of polypharmacy and PIMcog in Norwegian outpatients with MCI or d](https://medichelpline.com/clinical-feed/plos-one-14-one-year-pre-diagnostic-prevalence-and-associated-factors-of-polypharmacy-and.md)
- [Antihypertensive Drug Class and Risk of Incident Alzheimer’s Disease and Related Dementias: Replic](https://medichelpline.com/clinical-feed/medrxiv-17-antihypertensive-medication-class-and-incident-alzheimers-disease-and-related.md)
- [Capricor’s deramiocel for Duchenne appears headed for FDA rejection](https://medichelpline.com/clinical-feed/stat-news-1-stat-capricor-therapeutics-duchenne-treatment-is-heading-for-an-fda-rejection.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.